Keeping Current in Atopic Diseases
1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a record presentation for NAPNAP's 2025 National Conference.
This presentation will focus on the treatment of common dysrhythmias seen in children, specifically pharmacologic options. We will review both inpatient and outpatient management of various dysrhythmias.
NAPNAP’s Asthma and Allergy SIG is pleased to support this session.
This archived presentation from our 2025 national conference is available only as part of a bundle of pharmacology courses recorded during our 2025 conference in Chicago. Purchase the 2025 Pediatric Pharmacology Bundle and gain access to all five courses. To see the complete listing of courses available for selection in the 2025 conference bundle, click here.
The 2025 Pediatric Pharmacology Bundle activity is offered at a member-only discounted rate of $65. Non-members may purchase this bundle for $145. Great news - You can join NAPNAP before purchasing to save.
Please note that this program is a recording from a live session from NAPNAP 2025 national conference in Chicago. If you earned CE for this session, this course will be a duplicate.
IMPORTANT: You must be logged in using your NAPNAP Username and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any payment information.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: [email protected]
Copyright 2025 © by National Association of Pediatric Nurse Practitioners
Target Audience
Pediatric-focused advanced practice registered nurses.
Learning Objectives
• Describe the newly approved biologic omalizumab and why it improves safety for food allergy.
• Describe the role of immunotherapy for the treatment of food allergy and allergic rhinitis.
• Define the patients that should be considered for biologic therapies.
Megan O. Lewis, MSN, RN, CPNP- PC
Maria Crain, MSN, APRN, CPNP-PC
Elizabeth Hanna, MSN, RN, CPNP-PC
There are no disclosures to report
Available Credit
- 1.25 Contact hours

Facebook
X
LinkedIn
Forward